What’s going on with generic versions of Vandetanib?

Vandetanib is a targeted anti-cancer drug developed by AstraZeneca. It is mainly used to treat advanced medullary thyroid cancer (MTC; thyroid cancer). It is one of the first targeted drugs targeting the RET mutation pathway. The drug was approved by the US FDA for marketing in April 2011 under the trade name Caprelsa. With its inhibitory effect on the triple signaling pathway of RET, VEGFR and EGFR, vandetanib has significantly improved the disease control rate of some patients with advanced thyroid cancer. However, due to high research and development costs and long patent protection periods, the drug has been under patent protection worldwide for a long time, which is the main reason why no generic drugs have yet been released.

In terms of generic drug research, a few pharmaceutical companies have started bioequivalence studies on the synthesis and formulation of vandetanib's active ingredients, but they are still in the early stages. According to public information, vandetanib's core patents cover multiple aspects such as chemical structure, preparation formula and crystalline characteristics, making it more difficult to imitate. In particular, its dissolution characteristics and stability requirements are relatively strict, and specific processes are required to ensure that the in vivo absorption is consistent with that of the original drug. Because of this, even though some countries have begun pharmaceutical equivalence trials, there is currently no generic version that has passed full registration approval.

In the Chinese market, vandetanib tablets have not yet been officially launched, so there are currently no domestic generic drugs or imported substitutes. Due to the lack of registration information, its medical insurance payment, price and supply channels are temporarily unavailable. According to overseas pricing, Caprelsa 300mg*30 tablets are priced at about 45,000 yuan, which falls into the category of high-priced targeted drugs. This also means that if it enters the Chinese market in the future, price and accessibility issues will become the primary focus.

Overall, the development of generic versions of vandetanib is still in its early stages, and there are no alternative versions approved for marketing yet. Its future introduction time in the domestic market depends on regulatory approval, technical barriers and the expiration of the original drug patent.

Reference materials:https://www.drugs.com/caprelsa.html